FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118077078> ?p ?o ?g. }

• W2118077078 endingPage "3290" @default.
• W2118077078 startingPage "3284" @default.
• W2118077078 abstract "Purpose Hereditary retinoblastoma (Rb) survivors have increased risk of subsequent malignant neoplasms (SMNs). Previous studies reported elevated radiotherapy (RT) -related SMN risks, but less is known about chemotherapy-related risks. Patients and Methods In a long-term follow-up study of 906 5-year hereditary Rb survivors diagnosed from 1914 to 1996 and observed through 2009, treatment-related SMN risks were quantified using cumulative incidence analyses and multivariable Cox proportional hazards regression models with age as the underlying time scale. Results Nearly 90% of Rb survivors were treated with RT, and almost 40% received alkylating agent (AA) –containing chemotherapy (predominantly triethylenemelamine). Median follow-up time to first SMN diagnosis was 26.3 years. Overall SMN risk was not significantly elevated among survivors receiving AA plus RT versus RT without chemotherapy (hazard ratio [HR], 1.27; 95% CI, 0.99 to 1.63). AA-related risks were significantly increased for subsequent bone tumors (HR, 1.60; 95% CI, 1.03 to 2.49) and leiomyosarcoma (HR, 2.67; 95% CI, 1.22 to 5.85) but not for melanoma (HR, 0.74; 95% CI, 0.36 to 1.55) or epithelial tumors (HR, 0.89; 95% CI, 0.48 to 1.64). Leiomyosarcoma risk was significantly increased for survivors who received AAs at age < 1 (HR, 5.17; 95% CI, 1.76 to 15.17) but not for those receiving AAs at age ≥ 1 year (HR, 1.75; 95% CI, 0.68 to 4.51). Development of leiomyosarcoma was significantly more common after AA plus RT versus RT (5.8% v 1.6% at age 40 years; P = .01). Conclusion This comprehensive quantification of SMN risk after chemotherapy and RT among hereditary Rb survivors also demonstrates an AA-related contribution to risk. Although triethylenemelamine is no longer prescribed, our findings warrant further follow-up to investigate potential SMN risks associated with current chemotherapies used for Rb." @default.
• W2118077078 created "2016-06-24" @default.
• W2118077078 creator A5000437754 @default.
• W2118077078 creator A5027558137 @default.
• W2118077078 creator A5030467967 @default.
• W2118077078 creator A5036136202 @default.
• W2118077078 creator A5047847872 @default.
• W2118077078 creator A5050414089 @default.
• W2118077078 creator A5057142749 @default.
• W2118077078 date "2014-10-10" @default.
• W2118077078 modified "2023-10-05" @default.
• W2118077078 title "Risk of Subsequent Malignant Neoplasms in Long-Term Hereditary Retinoblastoma Survivors After Chemotherapy and Radiotherapy" @default.
• W2118077078 cites W10347719 @default.
• W2118077078 cites W1839076539 @default.
• W2118077078 cites W1969638003 @default.
• W2118077078 cites W1969648797 @default.
• W2118077078 cites W1970615351 @default.
• W2118077078 cites W1971494627 @default.
• W2118077078 cites W1978953017 @default.
• W2118077078 cites W1982833543 @default.
• W2118077078 cites W2003192349 @default.
• W2118077078 cites W2009934230 @default.
• W2118077078 cites W2013863113 @default.
• W2118077078 cites W2015554033 @default.
• W2118077078 cites W2022645679 @default.
• W2118077078 cites W2023271413 @default.
• W2118077078 cites W2023719828 @default.
• W2118077078 cites W2034042951 @default.
• W2118077078 cites W2050516355 @default.
• W2118077078 cites W2055662527 @default.
• W2118077078 cites W2060658196 @default.
• W2118077078 cites W2063630829 @default.
• W2118077078 cites W2064986772 @default.
• W2118077078 cites W2066689762 @default.
• W2118077078 cites W2070445467 @default.
• W2118077078 cites W2073140442 @default.
• W2118077078 cites W2073617751 @default.
• W2118077078 cites W2077858999 @default.
• W2118077078 cites W2078479980 @default.
• W2118077078 cites W2082672149 @default.
• W2118077078 cites W2085149503 @default.
• W2118077078 cites W2085797732 @default.
• W2118077078 cites W2086224937 @default.
• W2118077078 cites W2087023624 @default.
• W2118077078 cites W2097761061 @default.
• W2118077078 cites W2102400509 @default.
• W2118077078 cites W2102706108 @default.
• W2118077078 cites W2105363094 @default.
• W2118077078 cites W2108539626 @default.
• W2118077078 cites W2123528350 @default.
• W2118077078 cites W2124966703 @default.
• W2118077078 cites W2126034416 @default.
• W2118077078 cites W2136400910 @default.
• W2118077078 cites W2136770973 @default.
• W2118077078 cites W2138460707 @default.
• W2118077078 cites W2140618265 @default.
• W2118077078 cites W2142761201 @default.
• W2118077078 cites W2143351780 @default.
• W2118077078 cites W2147606107 @default.
• W2118077078 cites W2156763392 @default.
• W2118077078 cites W2158521171 @default.
• W2118077078 cites W2164157837 @default.
• W2118077078 cites W2169278972 @default.
• W2118077078 cites W2443282077 @default.
• W2118077078 cites W3024626787 @default.
• W2118077078 cites W4254892493 @default.
• W2118077078 doi "https://doi.org/10.1200/jco.2013.54.7844" @default.
• W2118077078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4178525" @default.
• W2118077078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25185089" @default.
• W2118077078 hasPublicationYear "2014" @default.
• W2118077078 type Work @default.
• W2118077078 sameAs 2118077078 @default.
• W2118077078 citedByCount "99" @default.
• W2118077078 countsByYear W21180770782014 @default.
• W2118077078 countsByYear W21180770782015 @default.
• W2118077078 countsByYear W21180770782016 @default.
• W2118077078 countsByYear W21180770782017 @default.
• W2118077078 countsByYear W21180770782018 @default.
• W2118077078 countsByYear W21180770782019 @default.
• W2118077078 countsByYear W21180770782020 @default.
• W2118077078 countsByYear W21180770782021 @default.
• W2118077078 countsByYear W21180770782022 @default.
• W2118077078 countsByYear W21180770782023 @default.
• W2118077078 crossrefType "journal-article" @default.
• W2118077078 hasAuthorship W2118077078A5000437754 @default.
• W2118077078 hasAuthorship W2118077078A5027558137 @default.
• W2118077078 hasAuthorship W2118077078A5030467967 @default.
• W2118077078 hasAuthorship W2118077078A5036136202 @default.
• W2118077078 hasAuthorship W2118077078A5047847872 @default.
• W2118077078 hasAuthorship W2118077078A5050414089 @default.
• W2118077078 hasAuthorship W2118077078A5057142749 @default.
• W2118077078 hasBestOaLocation W21180770781 @default.
• W2118077078 hasConcept C104317684 @default.
• W2118077078 hasConcept C120665830 @default.
• W2118077078 hasConcept C121332964 @default.
• W2118077078 hasConcept C126322002 @default.
• W2118077078 hasConcept C141071460 @default.
• W2118077078 hasConcept C143998085 @default.

• next